LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Natus Medical Incorporated (“Natus” or the “Company”) (Nasdaq: BABY). Investors who purchased or otherwise acquired Natus shares between October 16, 2015 and April 3, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 31, 2017 lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Complaint alleges that during the Class Period, the Company made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects, including that: the Venezuelan government did not issue tens of millions of dollars in prepayments to the Company, which were needed in October 2015; that Natus did not have the means to properly implement its rights under its supply contract, as Venezuela was the only means of resolving the dispute; Natus’ receipt of revenues regarding the supply contract was dependent on the result of Venezuelan elections; and as a result, Natus was not prepared to achieve the increased guidance rendered by Defendants, which lacked a reasonable basis.
When this information was revealed to the investing public, the value of Natus fell, causing investors harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.